Huifen Chen

11PUBLICATIONS
18CO-AUTHORS
Molecular targetsNeural engineeringGene and molecular therapyToxicology (incl. clinical toxicology)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 18, 2026
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models.

|Oct 30, 2025
Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory Diseases.

Snahel Patel, Huifen Chen, Eugene Varfolomeev

|May 21, 2025
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models".

Michael Berlin, Jennifer Cantley, Mark Bookbinder

|Mar 03, 2024
Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease.

Jack A Terrett, Justin Q Ly, Paula Katavolos

|Jan 05, 2024
PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models.

Michael Berlin, Jennifer Cantley, Mark Bookbinder

|Nov 15, 2021
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors.

Dennis X Hu, Snahel Patel, Huifen Chen

Pageof 2

Frequent Collaborators

4 joint publications

Jack A Terrett

3 joint publications

Peter S Dragovich

3 joint publications

Christopher M Rose

2 joint publications

Adam R Johnson